EICHOR
● Active Not Recruiting
REal-life ON PARKinson's - ITaly (REONPARK-IT)
Condition: Parkinson Disease · Sponsor: Bial - Portela C S.A.
About this study
The present study aims to evaluate the effectiveness and safety of opicapone in a real-world setting at centers for Parkinson's disease located in Italy.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (20)
| Policlinico di Bari Ospedale Giovanni XXIII, Clinica Neurologia AMADUCCI | Bari, Italy | — |
| ASST Spedali Civili di Brescia | Brescia, Italy | — |
| ARNAS Azienda Ospedaliera Brotzu | Cagliari, Italy | — |
| Ospedale Mater Domini | Catanzaro, Italy | — |
| Ospedale SS Annunziata | Chieti, Italy | — |
| Ospedale Policlinico San Martino | Genova, Italy | — |
| Centro Neurolesi Bonino Pulejo Messina/IRCCS | Messina, Italy | — |
| ASST Gaetano Pini CTO, Centro Parkinson | Milan, Italy | — |
| Istituto Neurologico Carlo Besta - Fondazione IRCCS | Milan, Italy | — |
| U.O di Neurologia, Policlinico P. Giaccone | Palermo, Italy | — |
| Fondazione Mondino | Pavia, Italy | — |
| Azienda Ospedaliera di Perugia (Santa Maria della Misericordia) | Perugia, Italy | — |
+ 8 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07403799